Telaprevir is the first hepatitis C drug that has demonstrated activity in patients who have failed prior therapy. In patients who received peginterferon alfa-2a and ribavirin for a year, the addition of telapravir for 24 weeks achieved a sustained virologic response(SVR) of 53% compared to 14% in patients who did not receive telapravir.It is thought that some patients who accomplish this outcome may be cured of Hepatitis, a feat rarely accomplished before. In a second randomized controlled trial (REALIZE) of patients who had previously relapsed or had only a partial response, rates of SVR were higher in patients treated with telaprevir (83% to 88%) compared to 24% in controls. In a third trial (ADVANCE) for previously untreated patients, patients taking telaprevir had a SVR (69% to 75%) versus 44% in the control group.
Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). “Telaprevir”. Drugs of the Future 32 (9): 788.
Irena Melnikova (2008). “Hepatitis C therapies”. Nature Reviews Drug Discovery 7 (10): 799–800.
McHutchison JG, Manns MP, Muir AJ, et al. (2010). “Telaprevir for previously treated chronic HCV infection”. N Engl J Med 362 (14): 1292–303.
Zeuzem S, Andreone P, Pol S, et al. (2011). “Telaprevir for retreatment of HCV infection.”. N Engl J Med 364 (25): 2417–28.
Jacobson IM, McHutchison JG, Dusheiko G, et al. (2011). “Telaprevir for previously untreated chronic hepatitis C virus infection.”. N Engl J Med 364 (25): 2405–16
Read the Layperson version here.